Sun Pharma secures ex-US, ex-China rights to cholesterol drug lerodalcibep
Sun Pharma has licensed exclusive rights to manufacture and commercialise LIB Therapeutics’ PCSK9 inhibitor lerodalcibep outside the US and China, targeting a global cholesterol-drug market estimated at $3.7 billion. LIB will receive upfront, milestone and royalty payments.
The development
Sun Pharma signed a licensing deal for the $3.7 billion PCSK9-inhibitor market, gaining exclusive rights to manufacture and commercialise Lerodalcibep outside the US and China. LIB Therapeutics will receive upfront, milestone and royalty payments.
The numbers
- $3.7 billion
- 38 per cent
- two years
- June 2026
- $2.9 billion
- September 21
- 300 mg
- 25 degrees Celsius
- six months
- 33 per cent
Why it matters to operators and investors
The deal secures exclusive regional rights to a differentiated PCSK9 inhibitor, reinforcing Sun Pharma’s strategy of licensing late-stage assets to expand beyond its core portfolio.
What to watch next
- Regulatory submission and approval timelines for lerodalcibep in major licensed territories.
- Publication of additional clinical efficacy, safety, durability, and real-world evidence.
- Pricing, reimbursement, and formulary decisions in initial launch markets.
- Milestone-payment disclosures and management commentary on expected launch timing.
- Competitive launches, label expansions, biosimilar developments, or price cuts among LDL-lowering therapies.
- Sun Pharma disclosures on specialty-revenue mix, cardiovascular field-force investment, and manufacturing readiness.
- Prioritize regulatory filing sequences in markets where Sun has established specialty distribution and favorable cardiovascular reimbursement pathways.
- Build medical-affairs and payer evidence around LDL reduction, adherence, safety, and pharmacoeconomic value versus existing PCSK9 options.
- Negotiate country-specific pricing and access agreements before broad commercial rollout.
- Assess manufacturing capacity, cold-chain requirements, and launch inventory needs for a biologic specialty product.
- Use the asset to expand relationships with cardiologists, lipid clinics, and hospital procurement networks.
The counter-case
The headline overstates the immediacy of the opportunity: licensed rights do not create revenue until lerodalcibep clears regulators, secures reimbursement and is launched market by market. PCSK9 therapy is already a competitive category, with established injectable antibodies and newer long-acting alternatives, while payer restrictions and biosimilar/generic pressure on broader lipid treatments can limit uptake. Sun Pharma also inherits execution risk across diverse ex-US markets, and undisclosed upfront, milestone and royalty obligations could make the economics less attractive than the $3.7 billion market figure suggests.